This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Clarus Therapeutics Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Wichtige Informationen
43.9%
Wachstumsrate der Gewinne
49.8%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 23.2% |
| Wachstumsrate der Einnahmen | 29.6% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | n/a |
Jüngste Aktualisierungen zum künftigen Wachstum
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2025 | 62 | -8 | N/A | N/A | 1 |
| 12/31/2024 | 46 | -24 | N/A | N/A | 1 |
| 12/31/2023 | 32 | -35 | N/A | N/A | 1 |
| 12/31/2022 | 18 | -44 | N/A | N/A | 1 |
| 6/30/2022 | 17 | -24 | -57 | -57 | N/A |
| 3/31/2022 | 16 | -36 | -54 | -54 | N/A |
| 12/31/2021 | 14 | -40 | -44 | -44 | N/A |
| 9/30/2021 | 12 | -58 | -40 | -40 | N/A |
| 6/30/2021 | 10 | -50 | -40 | -40 | N/A |
| 3/31/2021 | 8 | -21 | -35 | -35 | N/A |
| 12/31/2020 | 6 | -10 | -42 | -42 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: CRXT.Q is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: CRXT.Q is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: CRXT.Q is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: CRXT.Q's revenue (29.6% per year) is forecast to grow faster than the US market (7.1% per year).
Hohe Wachstumseinnahmen: CRXT.Q's revenue (29.6% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Insufficient data to determine if CRXT.Q's Return on Equity is forecast to be high in 3 years time